Human Genome Sciences Announces First Quarter 2008 Financial Results and Key De... (2008 2007 ...)

Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments

Date:5/5/2008

2008 2007

(dollars in thousands, except share

and per share amounts)

Revenue - R&D contracts $12,275 $9,262

Costs and expenses:

Research and development (a) 72,554 47,179

General and administrative (b) 16,011 11,969

Total costs and expenses 88,565 59,148

Income (loss) from operations (76,290) (49,886)

Net investment income (expense) (3,144) (1,143)

Gain on sale of equity investment 32,518 -

Income (loss) before taxes (46,916) (51,029)

Provision for income taxes - -

Net income (loss) $ (46,916) $ (51,029)

Net income (loss) per share,

basic and diluted $(0.35) $(0.38)

Weighted average shares

outstanding, basic & diluted 135,284,778 134,031,371

(a) Includes stock-based compensation expense of $2,501 ($0.02 per share)

and $2,970 ($0.02 per share) for the three months ended March 31, 2008

and 2007, respectively.

(b) Includes stock-based compensation expense of $1,962 ($0.02 per share)

and $2,049 ($0.02 per share) for the three months ended March 31, 2008

and 2007, respectively.

CONSOLIDATED BALANCE SHEET DATA:

As of As of

March 31, December 31,

2008 2007

(dollars in thousand
'/>"/>

Post Your Comments:

Human Genome Sciences Announces First Quarter 2008 Financial Results and Key De...(2008 2007 ...)